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Background. Depression is associated with an increased risk of cardiovascular disease in human immunodeficiency virus 
(HIV). We hypothesized that reducing depressive symptoms would improve HIV-related cardiovascular risk.
Methods. We conducted a single-center, randomized (1:1), controlled, parallel-group, assessor-blinded, pilot trial comparing 
Beating the Blues US (BtB)—an evidence-based, 8-session, internet cognitive-behavioral therapy for depression—with usual care 
(UC) in HIV-positive participants receiving virologically suppressive antiretroviral therapy and with Patient Health Questionnaire 
(PHQ)-9 scores ≥10. The primary endpoint was change in brachial artery flow-mediated dilation (FMD) at 12 weeks. Secondary 
endpoints were FMD change at 24 weeks and inflammation, coagulation, and metabolic biomarker changes at 12 and 24 weeks.
Results. Fifty-four participants were randomized (27 in each arm). Mean reductions in PHQ-9 scores were significantly greater 
with BtB versus UC at 12 weeks (−5.60 vs −1.52; P = .007) and 24 weeks (−6.00 vs −1.38; P = .008); reductions in the Hopkins 
Symptom Checklist Depression Scale-20 scores were also significantly greater with BtB versus UC at 24 weeks (−0.72 vs −0.35; 
P = .029). Changes in FMD between arms were not significantly different at 12 or 24 weeks. Significantly larger reductions in soluble 
(s)CD14 and sCD163 with BtB versus UC were found at 12 and 24 weeks, respectively.
Conclusions. Compared with UC, internet cognitive-behavioral therapy using BtB resulted in greater improvements in depres-
sive symptoms and monocyte activation markers but did not improve FMD in this pilot trial. These data support performing larger 
studies to determine the potential salutatory effects of behavioral therapies for depression on HIV-related inflammation.
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Depression has been linked to a higher risk of cardiovascular 
disease (CVD) in the general population [1, 2], and prelimi-
nary evidence suggests that successful depression treatment 
may reduce the risk of first CVD events [3]. Although behav-
ioral factors (smoking, poor medication adherence, sedentary 
lifestyle) associated with depression may partially account for 
this increased risk, depression may also contribute to athero-
sclerosis development through its association with heightened 
systemic inflammation [4, 5] and endothelial dysfunction 
[6]. Inflammation, and specifically monocyte activation [7, 
8], is greater in people with human immunodeficiency virus 
(PWH) compared with human immunodeficiency virus (HIV)-
negative people, even when PWH are receiving virologically 
suppressive antiretroviral therapy (ART) [9]. Moreover, greater 
circulating levels of markers of systemic inflammation (high-
sensitivity C-reactive protein [hsCRP], interleukin-6 [IL-6]) 
[10] and monocyte activation (soluble [s]CD14, sCD163) [11, 
12] are associated with incident HIV-CVD. Thus, it stands to 
reason that depression, possibly through greater levels of sys-
temic inflammation and worse endothelial function, may con-
tribute to the increased risk of CVD observed in PWH [13]. In 
fact, we recently demonstrated an increased risk of acute myo-
cardial infarction [14] and congestive heart failure [15] in PWH 
with depression versus those without depression. As such, we 
hypothesized that treating depressive symptoms would reduce 
HIV-CVD risk, specifically through improved endothelial func-
tion measured as brachial artery flow-mediated dilation (FMD) 
and through a reduction in systemic inflammation. To test this 
hypothesis, we performed a pilot, randomized, controlled trial 
comparing an internet cognitive-behavioral therapy (CBT) 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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program for depression called Beating the Blues US (BtB) with 
usual care (UC) for depression to improve FMD and reduce 
markers of systemic inflammation in PWH on ART.
METHODS
Study Design
The design of our 24-week pilot trial is shown in Figure 1. The 
blood specimens obtained during the trial were archived for 
later batch testing of biomarkers of interest, and FMD of the 
brachial artery was measured as a marker of physiologic endo-
thelial function. Because we have observed a possible “regres-
sion to the mean” effect in FMD in our previous trials with high 
outlier values at baseline [16, 17], we chose to perform 2 Entry 
visits, spaced between 1 and 15 days apart, for which biomarker 
and FMD measurements were averaged to obtain more stable 
baseline estimates. At the Second Entry Visit, participants were 
randomized 1:1, stratified by current use of antidepressant 
medications (yes/no), to either BtB or UC. The randomization 
sequence was computer-generated with study arm allocation 
assigned centrally. Participants then underwent similar pro-
cedures at Week 12 and Week 24 after the Second Entry Visit. 
Mental health questionnaires were also completed at the Second 
Entry, Week 12, and Week 24 Visits. Fasting and smoking ces-
sation for at least 8 hours were required before each study visit. 
The endpoint assessors were blinded to study arm assignment. 
Those randomized to BtB underwent up to 8 weekly therapy 
sessions between the Second Entry Visit and Week 12.
All participants provided written, informed consent. 
The study was conducted in accordance with the Helsinki 
Declaration, was approved by the Indiana University (IU) 
Institutional Review Board, and was registered at ClinicalTrials.
gov (NCT02309372).
Study Population
All participants were recruited from the HIV clinics at the 
IU Medical Center. All were HIV-positive, at least 18 years of 
age, had received ART (of any kind) for at least 1 year before 
screening, had an HIV-1 ribonucleic acid (RNA) level <75 
copies/mL at screening, and had a Patient Health Questionnaire 
(PHQ)-9 score ≥10 at screening, which indicates clinically rel-
evant depression symptoms [18]. Exclusion criteria included 
active suicidality, history of schizophrenia or bipolar dis-
order, known CVD or other proinflammatory condition (ex-
cept for hepatitis B or C coinfection), systolic/diastolic blood 
pressures >160/110  mmHg, estimated glomerular filtration 
rate <50 mL/min per 1.73 m2, screening glucose ≥140 mg/dL 
or HgbA1c >8.0%, screening total cholesterol >240 mg/dL, and 
pregnancy or breastfeeding during the study. Use of any other 
form of depression treatment was allowed throughout the trial.
Study Intervention
Beating the Blues US (UPMC Health Plan; see www.
beatingthebluesus.com for a video tutorial) is an empirically 
supported, stand-alone, internet cognitive-behavioral treat-
ment program for depression appropriate for adults with little 
computer experience and at least a 5th–6th grade reading level 
[19]. Beating the Blues US utilizes an interactive, multimedia 
format to deliver eight 50-minute, weekly sessions, the struc-
ture and content of which mirror face-to-face CBT. Although 
sessions are tailored to each patient’s problems, general topics 
include challenging dysfunctional thoughts, activity sched-
uling, problem solving, graded exposure, task breakdown, sleep 
management, and relapse prevention. Patients are also assigned 
tailored home work.
Beating the Blues US sessions occurred at a location selected 
by the participant where they could access the internet or an 
investigator’s (J.C.S.) laboratory. Participant preference deter-
mined the location. Regardless of location, study personnel 
provided support to participants working through BtB by sched-
uling sessions, identifying and collecting homework, assisting 
with technical issues, and addressing questions. Participants 
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Figure 1. Design of the 24-week, pilot, randomized, controlled trial showing study visits and associated study measurements. FMD, flow-mediated dilation.
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We chose to use BtB as our intervention, because it is effica-
cious for depression, acceptable to patients [19], and scalable 
because of its internet delivery. Beating the Blues US has con-
siderable empirical support, including positive clinical trials 
of 274 [20, 21] and 704 [22] primary care patients. Beating the 
Blues US is a potent intervention, with effect sizes comparable 
to face-to-face CBT [20, 21]. Moreover, we chose a behavioral 
intervention to avoid drug interactions between antidepressants 
and ART and to avoid confounding by potentially direct effects 
of antidepressants (as opposed to effects mediated through de-
pression) on our study endpoints.
Those randomized to UC did not receive any study-provided 
treatments for depression. The UC participants were informed 
of their depression diagnosis and were encouraged to follow-up 
with their primary care or HIV provider. We also sent their pri-
mary provider a letter immediately after the Second Entry Visit 
indicating that their patient had a depressive disorder and was 
randomized to UC; the letter also included a list of local mental 
health services. Otherwise, there was no formal interaction 
with the UC participants between the Second Entry Visit and 
the Week 12 Visit. No restrictions on receipt of new depression 
therapies were placed on any study participant at any time; any 
new or changes in depression treatments (pharmacologic or be-
havioral) were recorded at each study visit.
Study Endpoints
The primary endpoint was change in FMD at Week 12. 
Secondary endpoints were change in FMD at Week 24 and 
changes in the biomarkers at Weeks 12 and 24.
Flow-mediated dilation was measured per consensus guide-
lines [23] using a GE LOGIQe high-resolution ultrasound 
with a 15-MHz vascular transducer. A blood pressure cuff was 
placed around the forearm and inflated to 250  mmHg for 5 
minutes. Changes in brachial artery diameter from preinflation 
to 60 and 90 seconds after cuff deflation were measured with the 
greater change in diameter recorded for analysis. Nitroglycerin-
mediated dilation (NTGMD) was also assessed as an internal 
control. Measurements were made using AccessPoint 2011 soft-
ware (version 8.2; Freeland Systems).
Biomarkers of systemic and vascular inflammation (hsCRP, 
R&D Systems), IL-6 (R&D Systems), soluble vascular cell adhe-
sion molecule-1 ([sVCAM-1] R&D Systems), monocyte immune 
activation (sCD14 and sCD163, both from R&D Systems), and co-
agulation (D-dimer, Thermo Scientific; fibrinogen, Abnova) were 
measured by standard enzyme-linked immunosorbent assay kits 
per manufacturer instructions at each study visit. Also measured 
were cholesterol fractions, glucose, and insulin levels. All assays 
were performed by the Center for Diabetes and Metabolic Diseases 
Translational Core at the IU School of Medicine.
Changes in depression symptom severity scores were as-
sessed using both the PHQ-9 and the Hopkins Symptom 
Checklist Depression Scale (SCL)-20. Changes in smoking 
status, antiretroviral and antidepressant medications, and new 
diagnoses were ascertained at each study visit.
Statistical Analysis
Continuous variables were summarized by treatment groups 
using descriptive statistics. Categorical variables were summar-
ized using frequency counts and percentages. Student’s t tests 
were performed to compare changes for the primary and sec-
ondary endpoints between the BtB group (both the full BtB 
group and the subset of those who completed at least 6 sessions 
[BtB6-8]) and the UC group from Entry to both Week 12 and 
Week 24. Because this was a pilot trial, no corrections for mul-
tiple testing were performed to identify potential relationships 
of interest to be verified in future larger trials. Pearson correl-
ations were also calculated between FMD and the depression 
severity measures. Two-sided P < .05 were considered statisti-
cally significant.
Due to the few missing FMD and SCL-20 data (Figure  2), 
multiple imputation methods using SAS PROC MI were used 
to substitute imputed values where FMD, baseline diameter, 
and SCL-20 were missing at each time point, based on the 
nonmissing values from other participants and all participants’ 
age, sex, and race.
Because we specifically wished to evaluate the effects of 
covariates on the primary outcomes, we also performed mul-
tiple linear regressions adjusted for study group on the changes 
in FMD. In these models, the indicator variable for study arm 
was kept regardless of its significance, whereas other potential 
baseline covariates were then included. All analytic assump-
tions were verified and all analyses were performed with SAS 
v9.4 (SAS Institute, Cary, NC).
RESULTS
The characteristics of the study groups at Entry are shown in 
Table  1. The study group overall consisted primarily of black 
men. Overall, the participants had high CD4 cell counts 
with two thirds receiving antidepressant medications. The 
types of antidepressants received were similar in both groups 
(Supplementary Table 1). All participants had HIV-1 RNA <75 
copies/mL, both at screening and at the Second Entry Visit at 
the time of randomization. The majority of participants were 
receiving emtricitabine/tenofovir combined with integrase in-
hibitors (Supplementary Table 2), with similar numbers in each 
group receiving efavirenz and abacavir. The BtB and UC groups 
were similar except for somewhat lower PHQ-9 scores in the 
UC group (although the SCL-20 scores were similar between 
groups). Also shown in Table  1 are the characteristics of the 
BtB6-8 subgroup of 15 participants. These latter participants did 
not appreciably differ from the total 27 randomized to BtB.
The flow of the participants through the trial is shown in 
Figure 2. The 54 participants were evenly allocated to each study 
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group. Of the 27 in each study arm, 25 completed the Week 12 
visit; 24 and 25 completed the Week 24 study visit in the BtB 
and UC arms, respectively. There were few losses in FMD (1 at 
Week 12 and 2 and Week 24 in BtB; 4 at Week 24 in UC) and 
biomarker data (2 at Week 12 and 1 at Week 24 in BtB; 1 at Week 
12 and 5 at Week 24 in UC) due to unreadable imaging and 
sample unavailability as outlined in Figure 2.
Human immunodeficiency virus-1 RNA levels increased 
to ≥75 copies/mL at Week 12 in 4 BtB participants (actual values: 
154, 225, 664, and 5070 copies/mL) and 3 UC participants (ac-
tual values: 111, 121, and 822 copies/mL). At Week 24, HIV-1 
RNA levels were ≥75 copies/mL in 4 BtB participants (actual 
values: 84, 95, 153, and 24 100 copies/mL) and 1 UC participant 
(actual value: 3950 copies/mL). Changes in ART during the trial 
were infrequent with 2 switches from efavirenz to bictegravir in 
the UC arm and 2 switches from efavirenz to bictegravir and 
elvitegravir-cobicistat in the BtB arm (1 each). No changes in 
antidepressant medications were observed during the trial.
Depression Symptoms Severity Changes
The PHQ-9 and SCL-20 scores decreased (ie, improved) in 
both study groups as shown in Figure 3. The PHQ-9 scores im-
proved significantly more in the BtB group compared with the 
UC group at Week 12 (P = .007) and Week 24 (P = .008). The 
SCL-20 scores also improved more in the BtB group compared 
with UC at Weeks 12 and 24, but only significantly so at Week 
24 (P = .029). Even greater decreases in both scores were ob-
served in the BtB6-8 subgroup compared with UC.
Vascular Function Changes
The values of the vascular measurements are shown in Table 2. 
Brachial artery diameters, NTGMD, and reactive hyperemia 
velocity time integrals were stable in each group during the 
trial. Flow-mediated dilation decreased (ie, worsened) in both 
groups, with no significant differences between arms in unad-
justed analyses (Figure 4).
However, in models adjusted for (1) Entry FMD, (2) Entry 
FMD and persistent HIV-1 RNA level <75 copies/mL during 
the trial, (3) Entry FMD and Entry ART type (protease in-
hibitor vs nonnucleoside reverse-transcriptase inhibitor vs 
integrase strand transfer inhibitor), (4) Entry FMD and Entry 
SCL-20, and (5) Entry FMD, Entry SCL-20, and Entry use of 
antidepressant medications, FMD at Week 12 (but not at Week 
24)  was significantly lower in the BtB6-8 subgroup compared 
with UC (all P < .05). The only adjusted model in which signif-
icantly lower FMD was observed at Week 12 in the overall BtB 
group versus UC was that which included Entry FMD and ART 
type; no significant differences were otherwise found between 
Assessed for eligibility (n=73)
Randomized (n=54)
Allocated to Usual Care (n=27)
Initially excluded (n=15)
Rescreened and found eligible (n=5)
Not meeting inclusion criteria (n=10)
Declined to participate (n=0)
Loss to follow-up prior to randomization (n=9)
5 did not complete any sessions
6 completed 1 sessions
1 completed 7 sessions
14 completed all 8 sessions
2 lost by week 12
1 additional lost by week 12 and week 24
1 completed 5 sessions
Allocated to beating the blues (n=27)
Lost to follow-up (n=3)
Available data
FMD (27 Entry, 24 week 12, 22 week 24)
Biomarkers (27 Entry, 23 week 12,
23 week 24)
Available data
FMD (26 Entry, 25 week 12, 21 week 24)
Biomarkers (27 Entry, 24 week 12,
20 week 24)
2 lost by week 12
Lost to follow-up (n=2)
Figure 2. Flow of the participants through the trial. FMD, flow-mediated dilation.
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the 2 main study groups in any other model at Week 12 or at 
Week 24.
Entry FMD and SCL-20 scores were significantly correlated 
(rho = −0.28; P = .04); Entry FMD and PHQ-9 scores were not 
correlated (rho = −0.082; P = .56). There were no significant 
correlations between changes in either SCL-20 or PHQ-9 with 
changes in FMD at Weeks 12 or 24 in the overall study cohort or 
in either study group (all rho <|0.18|; all P > .2).
Inflammation, Coagulation, and Metabolic Biomarker Changes
As shown in Figure 5, there were no significant differences in 
the changes between study groups in hsCRP, IL-6, or D-dimer 
at either Week 12 or Week 24. In addition, no significant dif-
ferences were found between the BtB6-8 subgroup and UC for 
these biomarkers. There were significantly greater reductions 
observed in sCD14 both in the BtB and BtB6-8 subgroup versus 
UC at Week 12; these differences persisted to a somewhat 
smaller degree at Week 24 and thus were no longer significant 
(Figure  6). There were no significant differences in sCD163 
between groups at Week 12, although there were significantly 
lower levels of this biomarker at Week 24 in the BtB and BtB6-8 
subgroup compared with UC (Figure 6). There were no signifi-
cant differences between study groups during the trial in either 
fibrinogen or sVCAM-1 levels (data not shown).
We did not observe significant differences between groups 
at Week 12 or 24 in cholesterol fractions (data not shown). 
As shown in Figure  7, there were nonsignificant improve-
ments in Homeostatic Model Assessment-Insulin Resistance 
(HOMA-IR) values in the BtB versus UC at Weeks 12 and 24 
and between the BtB6-8 subgroup versus UC at Weeks 12 and 24. 
We found significant improvements in systolic blood pressure 
with BtB compared with UC at Week 12 (−5.5 vs 2.8 mmHg; 
P = .009), but this did not persist at Week 24 (−3.9 vs 2.8 mmHg; 
P = .15). We did not find significant differences in diastolic 
blood pressures between BtB and UC at either Week 12 (−3.1 
vs 1.3 mmHg; P = .10) or Week 24 (−4.0 vs 1.1 mmHg; P = .11).
DISCUSSION
To our knowledge, this is the first trial assessing the efficacy of 
an internet CBT program for depression to improve CVD risk 
in PWH. We found that Beating the Blues US provided clinically 
Table 1. Characteristics of the Study Groups at Entrya
Characteristic
Usual Care  
(n = 27) Beating the Blues (n = 27)




Age, years 45.6 (11.9) 44.6 (9.8) 47.5 (10.1) 45.1 (10.8)
Female sex 5 (19) 4 (15) 4 (27) 9 (17)
Black race 15 (56) 21 (78) 12 (80) 36 (67)
Current smoker 12 (44) 10 (37) 2 (13.3) 22 (41)
CD4 cell count, µL 743 (396) 713 (243) 760 (245) 728 (325)
Body mass index, kg/m2 30.1 (6.7) 30.0 (7.0) 30.4 (8.7) 30.1 (6.7)
Systolic blood pressure, mmHg 123.5 (11.9) 127.7 (12.9) 127.3 (13.2) 125.6 (12.4)
Diastolic blood pressure, mmHg 77.7 (9.7) 80.0 (9.8) 78.4 (8.9) 77.4 (9.7)
Hemoglobin A1C, % 5.4 (0.7) 5.6 (0.5) 5.7 (0.6) 5.5 (0.6)
Estimated glomerular filtration rate, mL/min per 1.73 m2 88.5 (23.5) 98.9 (18.4) 91.9 (17.2) 93.7 (21.5)
Triglycerides, mmol/L 1.27 (0.52) 1.44 (0.97) 1.48 (1.15) 1.35 (0.77)
Total cholesterol, mmol/L 5.02 (0.96) 4.83 (1.02) 5.02 (1.09) 4.92 (0.99)
High-density lipoprotein cholesterol, mmol/L 1.26 (0.34) 1.21 (0.38) 1.20 (0.43) 1.23 (0.36)
Low-density lipoprotein cholesterol, mmol/L 3.53 (1.00) 3.21 (1.05) 3.47 (1.09) 3.37 (1.03)
Glucose, mmol/L 5.77 (0.57) 5.73 (0.71) 5.79 (0.84) 5.75 (0.64)
Insulin, µU/mL 13.93 (10.48) 16.47 (16.25) 18.28 (19.89) 15.20 (13.60)
HOMA-IR 3.72 (2.90) 4.50 (5.00) 5.12 (6.22) 4.1 (4.1)
PHQ-9 score 14.04 (4.32) 17.13 (4.96) 17.13 (5.08) 15.58 (4.87)
SCL-20 score 2.09 (0.63) 2.27 (0.92) 2.27 (1.06) 2.18 (0.78)
Antidepressant medication use 19 (70) 18 (67) 10 (67) 37 (69)
hsCRP, mg/L 4.32 (3.84) 4.65 (4.46) 5.53 (5.02) 4.49 (4.12)
IL-6, pg/mL 2.59 (1.65) 2.80 (2.15) 3.76 (2.36) 2.69 (1.90)
D-dimer, ng/mL 2430 (845) 2536 (878) 2880 (882) 2483 (855)
Fibrinogen, µg/mL 2756 (756) 2707 (667) 2094 (770) 2731 (706)
sCD14, ng/mL 2233 (621) 2325 (849) 2302 (829) 2279 (732)
sCD163, ng/mL 43.30 (21.27) 46.61 (12.03) 50.77 (10.14) 44.86 (17.19)
sVCAM-1, ng/mL 378 (108) 375 (135) 367 (84) 376 (121)
Abbreviations: HOMA-IR, homeostasis model assessment-insulin resistance; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; PHQ-9, Patient Health Questionnaire 9; s, soluble; 
SCL-20, Hopkins symptom checklist depression scale-20; sVCAM-1, soluble vascular cell adhesion molecule-1.
aData presented as mean (standard deviation) or n (%). The Beating the Blues6-8 subgroup comprised those randomized to Beating the Blues and completed at least 6 of the 8 treatment 
sessions.
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Table 2. Vascular Function Parameters of the Study Groups During the Triala
Vascular Parameter Time Point Usual Care Beating the Blues Beating the Blues6-8 Total
Baseline Diameter, cm      
 Entry 0.42 (0.06) 0.45 (0.06) 0.43 (0.06) 0.44 (0.06)
 Week 12 0.42 (0.06) 0.46 (0.05) 0.44 (0.06) 0.44 (0.06)
 Week 24 0.42 (0.06) 0.46 (0.06) 0.44 (0.06) 0.44 (0.06)
FMD, %      
 Entry 3.39 (1.78) 2.77 (1.76) 3.26 (2.00) 3.08 (1.78)
 Week 12 3.68 (2.99) 2.30 (2.19) 1.66 (2.39) 2.99 (2.69)
 Week 24 2.56 (2.51) 1.75 (1.19) 2.15 (1.24) 2.15 (1.99)
NTGMD, %      
 Entry 15.64 (4.99) 14.12 (5.55) 14.76 (6.26) 14.88 (5.28)
 Week 12 17.47 (6.87) 14.70 (5.58) 15.04 (6.49) 16.05 (6.32)
 Week 24 15.60 (6.33) 12.89 (4.31) 12.87 (4.49) 14.25 (5.51)
RHVTI, cm      
 Entry 0.64 (0.17) 0.53 (0.13) 0.50 (0.10) 0.58 (0.16)
 Week 12 0.59 (0.19) 0.51 (0.18) 0.49 (0.17) 0.56 (0.19)
 Week 24 0.61 (0.23) 0.52 (0.16) 0.52 (0.17) 0.56 (0.20)
Abbreviations: FMD, flow-mediated dilation; NTGMD, nitroglycerin-mediated dilation; RHVTI, reactive hyperemia velocity time integral.
aData presented as mean (standard deviation). The Beating the Blues6-8 subgroup comprised those randomized to Beating the Blues and completed at least 6 of the 8 treatment sessions.















































































































































Figure 3. Changes in Patient Health Questionnaire (PHQ)-9 and Hopkins Symptom Checklist Depression Scale (SCL-20) depression severity symptom scores during the trial 
between the Beating the Blues US (BtB) and Usual Care (UC) groups (A and C) and the BtB6-8 subgroup and UC group (B and D). SE, standard error.
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relevant [24] and statistically significant reductions in PHQ-9 
scores soon after treatment was completed (Week 12) and in 
PHQ-9 and SCL-20 scores at least 12 weeks afterwards (Week 
24). These improvements are similar to those found with BtB 
[20, 21] and with antidepressant medications [25] in general 
population studies. It is interesting to note that these improve-
ments were even more pronounced in the 15 participants who 
completed at least 6 of the planned 8 sessions (subgroup BtB6-8). 
Of note, these significant improvements occurred despite the 
number of participants in the intervention arm who did not 
take up BtB (11 of 27 completed only 0 or 1 session), which is 
similar to the nonuse rate found in BtB trials in other popula-
tions [20, 21]. Given that this depression treatment modality is 
highly practical for both patients and healthcare systems (it can 
be completed remotely, typically in the patient’s home), does 
not require access to behavioral health professionals, avoids the 
potential drug interactions and adverse effects of antidepres-
sant medications, and is readily scalable to large numbers of 
patients, there should be strong consideration towards using 
internet-based mental health strategies to address the wide-
spread unmet need for depression treatment in PWH.
Several studies have found cross-sectional associations be-
tween depression and impaired endothelial function [6], but 
causal relationships remain unclear. Thus, our primary objective 
was to determine whether improvement in depressive symptom 
severity translated to improvement in FMD in PWH. As found by 
others, we observed an inverse relationship between depressive 
symptom severity by SCL-20 score and FMD at Entry. However, 
we did not find differences between study groups in FMD change. 
In fact, FMD seemed to worsen in both study groups, with an un-
expectedly larger reduction in FMD in the BtB6-8 subgroup com-
pared with UC at Week 12, although these differences did not 
persist at Week 24. It is unclear whether the acute reductions in 
FMD were due to the observed modest increases in hsCRP and 
IL-6 at Week 12, were simply due to chance, or whether there was 
a true relationship between initial improvement in depression 
severity and transient worsening of endothelial function. Future 
studies are required to assess these possibilities.
Of note, there were similarly few participants in each study 
group who lost virologic control during the trial, with only 1 in 
each group with a marked increase in HIV viral load at Weeks 
12 and 24. As such, the within-group levels of FMD and bio-
markers and the between-group comparisons should not have 
been appreciably affected by these viral load elevations.
We also did not observe differences in changes between 
groups in several markers of systemic inflammation and coagu-
lation (hsCRP, IL-6, sVCAM-1, D-dimer, fibrinogen). However, 
we did find significant improvements in the BtB group com-
pared with UC in both sCD14 and sCD163, markers of mon-
ocyte activation. Depression has been linked to monocyte 
activation in the non-HIV population [26] and with higher 
levels of sCD14 in the HIV-positive population [27]. Other 
studies have suggested that depression, perhaps through vagus 
nerve neurocommunication, may alter gut microbiomes and 
enhance bacterial translocation, thereby triggering monocyte 
activation [28]. Thus, there is support for our findings of a pos-
sibly true causal relationship between depression and monocyte 
activation. Given that heightened monocyte activation has been 
linked to an increased risk of atherosclerosis [29], insulin resist-
ance [30], cognitive impairment [31], and overall mortality in 
PWH [12], our results suggest a mechanism by which depres-
sion is linked to these outcomes and also suggest an interven-
tion by which to reduce these risks.
We acknowledge several limitations to this study. The sample 
size was modest and may have precluded finding true differ-










































































Figure 4. Changes in flow-mediated dilation (FMD) during the trial between the Beating the Blues (BtB) and Usual Care (UC) groups (A) and the BtB6-8 subgroup and UC 
groups (B). SE, standard error.
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analysis using the actual sample sizes, the observed variability 
in changes in FMD from Entry to Week 12 (our primary study 
endpoint), and an alpha = 0.05 and beta = 0.20, we estimate 
that the minimally detectable difference in FMD change be-
tween study groups was 2.3%. We consider a difference of 1.0% 
to be clinically relevant because a 1.0% higher baseline FMD 
predicted a 6% lower risk of CVD events over 5 years in the 
Multi-Ethnic Study of Atherosclerosis (MESA) cohort study [32, 
33]. As such, our study was underpowered to detect such clin-
ically relevant differences in physiologic endothelial function 
measured using brachial artery FMD. In addition, although we 





























































































































































































































Figure 5. Changes in high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and D-dimer during the trial between the Beating the Blues (BtB) and Usual Care (UC) 
groups (A, C, and E) and the BtB6-8 subgroup and UC groups (B, D, and F). SE, standard error.
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various biomarkers, we only made these measurements once 
at Weeks 12 and 24 to minimize participant study burden and 
to reduce overall costs; as such, there may have been increased 
variability in these measurements during follow-up. The few 
numbers of women limited our ability to determine whether 
























































































































































P = .622 P = .024 P = .687 P = .037
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Figure 6. Changes in soluble (s)CD14 and sCD163 during the trial between the Beating the Blues (BtB) and Usual Care (UC) groups (A and C) and the BtB6-8 subgroup and 







































































P = .10 P = .053P = .14 P = .11
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Figure 7. Changes in Homeostatic Model Assessment-Insulin Resistance (HOMA-IR) during the trial between the Beating the Blues (BtB) and Usual Care (UC) groups (A) 
and the BtB6-8 subgroup and UC group (B). SE, standard error.
10 • ofid • Gupta et al
to be addressed in future trials given that women living with 
HIV may have greater levels of systemic inflammation and im-
mune activation [34, 35] and, thus, might benefit more than 
men from successful depression treatment. We cannot extrap-
olate our results to HIV-positive patients not on suppressive 
ART. We also performed several comparisons, so there is a risk 
for false-positive findings; although we found similarly reduced 
levels of both depression scores and monocyte activation bio-
markers, suggesting these effects are real. However, these lim-
itations are offset by the strengths of the study, including its 
randomized study design, the blinding of the outcome asses-
sors, and the few participants lost to follow-up.
CONCLUSIONS
In conclusion, an internet CBT program for depression sig-
nificantly improved depressive symptom severity and mon-
ocyte activation in PWH on suppressive ART. Larger trials 
are warranted to verify these preliminary results to improve 
depression and reduce the risk for both HIV and non-HIV 
serious events.
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Supplementary materials are available at Open Forum Infectious Diseases 
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